For ovarian carcinoma, the expression of Ki-67 antigen is widely used to guide clinical management, such as tumor aggression, vascular invasion, tumor metastasis, reserved prognosis, and poor response to chemotherapy [3, 13–16]. This evidence concerns the gene MKI67 and neoplasm.